Praxis' FDA decision on ulixacaltamide
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Pro members see it live.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Pro members see it live.
What the company said
“FDA reviews of relutrigine, with PDUFA target action date of December 27, 2026, and ulixacaltamide HCI, with PDUFA target action date of January 29, 2027, are ongoing”
More on PRAX and the FDA calendar
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Use this page
How to cite
Breakaway, Praxis' FDA decision on ulixacaltamide, Nov 16, 2026, getbreakaway.com/biotech/PRAX-ulixacaltamide
Journalists: email support@getbreakaway.com for the data behind this page.